shares of Adial Pharmaceuticals Inc (ADIL) on
Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. The company is headquartered in Charlottesville, Virginia and currently employs 3 full-time employees. The firm is focused on the development of a therapeutic agent for the treatment of alcohol use disorder (AUD). Its lead drug product is AD04. AD04 is a selective serotonin-3 antagonist. AD04 can also be used for the treatment of other addictive disorders, such as obesity, smoking, and drug addiction. The firm has completed a Phase-II clinical trials of AD04.